Estimation of kinetic parameters for curing of epoxy-anhydride compositions by DSC

© 2017, Springer Science+Business Media, LLC. The kinetics of the curing process of epoxy resin (ED-22) in the presence of the anhydride hardeners (iso-methyltetrahydrophthalic anhydride, hexahydrophthalic anhydride, and dodecylsuccinic anhydride) and accelerators (2-methyl imidazole and n-butyltriphenylphosphonium bromide) has been investigated by DSC method in the dynamic mode. Processing of experimental DSC thermograms recorded at different heating rates was carried out within the frameworks of isoconvertional analysis in two versions, namely "model-free" method of Friedman and the Ozawa—Flynn—Wall method. The possibility to describe the kinetics of epoxy compositions curing in the frameworks of one-step autocatalytic reaction model has been demonstrated. Obtained kinetic parameters were used to predict the curing kinetics under isothermal conditions and for comparative analysis of the compositions

Клинико-эпидемиологические аспекты работы Казанского центра экстрапирамидной патологии

Pathology of extrapyramidal nervous system (EP) is one of the most complex sections of clinical neurology. Specificity of EP disorders accounts for the necessity of specialized assistance to patients with parkinsonism, tremor, dystonias, tics and other hyperkinesias. The article gives an account of a 4-year experience of Center for Extrapyramidal pathology work, as well as its problems and achievements. A total of 1 738 patients with different motor disorders (total of 4 301 consultations) were examined in the center for the whole period of its existence. Scientific research work is carried on as well. On the basis of the experience it was found out that neurologists. Сome across considerable difficulties in making diagnosis and choice of extrapyramidal diseases treatment. We are planning to expand the use of modern techniques in diagnosis and treatment (including botulotoxin injections, deep brain stimulation), identification of epidemiology of some extrapyramidal disorders in Kazan city.Патология экстрапирамидной нервной системы представляет собой один из наиболее сложных разделов клинической неврологии. Специфичность экстрапирамидных расстройств диктует необходимость создания специализированной помощи пациентам с паркинсонизмом, тремором, дистониями, тиками и другими гиперкинезами. В данной статье описан четырехлетний опыт работы Центра экстрапирамидной патологии (г. Казань), его проблемы и успехи. За время существования центра проведено 4 301 консультация 1 738 пациентам с различными двигательными расстройствами, ведется научно-просветительская работа. Опыт работы показал, что неврологи испытывают значительные сложности в диагностике и выборе методов лечения экстрапирамидных заболеваний. Планируется расширение использования современных методов диагностики и лечения (в том числе инъекций ботулотоксина, глубокой стимуляции мозга), установление эпидемиологии отдельных экстрапирамидных заболеваний в г. Казани

Levodopa-carbidopa intestinal gel in the treatment of patients with parkinson disease: Results of a 12-month open study

© 2017, Media Sphera. All rights reserved.Objective: To evaluate the long-term safety and efficacy of intrajejunal levodopa-carbidopa intestinal gel (LCIG) infusion in the treatment of patients with severe stages of Parkinson disease (PD) who did not respond adequately to treatment with oral drugs. Material and methods: A large-scale international prospective open-label 54-week study of LCIG in patients with PD with severe motor fluctuations was carried out. A total of 48 patients were enrolled in Russia, 46 patients (95.8%) had PEG-J inserted, and 43 of them completed the study. The safety, including adverse events (AEs), infusion system and pump failures analysis, number of patients completely terminated the study, and efficacy (duration of “off” periods, “on” periods with or without troublesome dyskinesias, UPDRS scores, Clinical Global Impression, Quality of Life (PDQ-39, EQ-5D и EQ-VAS) dynamics, an analysis of patient’s diaries) were assessed throughout the whole study. Results: The majority of AEs were mild or moderate with most AEs connected with infusion system application (28.3% patients) including procedure pain. Serious AEs were registered in 8 patients (16.7%). 3 patients (6.3%) discontinued their participation in the study due to AEs. Mean duration of “off” periods by the end of the study decreased by 5.35±2.59 hours (p<0.001), duration of “on” periods without troublesome dyskinesia increased by 5.74±3.91 hours (p<0.001), reduction of “on” periods duration with troublesome dyskinesia became statistically significant by week 36 (p=0.020). The statistically significant improvement of UPDRS (generally and in respect to sub-scales), Clinical Global Impression, and Quality of Life scores was observed throughout the study. Levodopa dose remained stable throughout the 54 treatment weeks. Forty-three patients (93.5%) received LCIG monotherapy throughout the whole study. Conclusion: LCIG intrajejunal infusion during 54 weeks showed the favorable safety profile, high tolerability, and efficacy in PD motor symptoms correction

Estimation of kinetic parameters for curing of epoxy-anhydride compositions by DSC

© 2017, Springer Science+Business Media, LLC. The kinetics of the curing process of epoxy resin (ED-22) in the presence of the anhydride hardeners (iso-methyltetrahydrophthalic anhydride, hexahydrophthalic anhydride, and dodecylsuccinic anhydride) and accelerators (2-methyl imidazole and n-butyltriphenylphosphonium bromide) has been investigated by DSC method in the dynamic mode. Processing of experimental DSC thermograms recorded at different heating rates was carried out within the frameworks of isoconvertional analysis in two versions, namely "model-free" method of Friedman and the Ozawa—Flynn—Wall method. The possibility to describe the kinetics of epoxy compositions curing in the frameworks of one-step autocatalytic reaction model has been demonstrated. Obtained kinetic parameters were used to predict the curing kinetics under isothermal conditions and for comparative analysis of the compositions

Estimation of kinetic parameters for curing of epoxy-anhydride compositions by DSC

© 2017, Springer Science+Business Media, LLC. The kinetics of the curing process of epoxy resin (ED-22) in the presence of the anhydride hardeners (iso-methyltetrahydrophthalic anhydride, hexahydrophthalic anhydride, and dodecylsuccinic anhydride) and accelerators (2-methyl imidazole and n-butyltriphenylphosphonium bromide) has been investigated by DSC method in the dynamic mode. Processing of experimental DSC thermograms recorded at different heating rates was carried out within the frameworks of isoconvertional analysis in two versions, namely "model-free" method of Friedman and the Ozawa—Flynn—Wall method. The possibility to describe the kinetics of epoxy compositions curing in the frameworks of one-step autocatalytic reaction model has been demonstrated. Obtained kinetic parameters were used to predict the curing kinetics under isothermal conditions and for comparative analysis of the compositions

Estimation of kinetic parameters for curing of epoxy-anhydride compositions by DSC

© 2017, Springer Science+Business Media, LLC. The kinetics of the curing process of epoxy resin (ED-22) in the presence of the anhydride hardeners (iso-methyltetrahydrophthalic anhydride, hexahydrophthalic anhydride, and dodecylsuccinic anhydride) and accelerators (2-methyl imidazole and n-butyltriphenylphosphonium bromide) has been investigated by DSC method in the dynamic mode. Processing of experimental DSC thermograms recorded at different heating rates was carried out within the frameworks of isoconvertional analysis in two versions, namely "model-free" method of Friedman and the Ozawa—Flynn—Wall method. The possibility to describe the kinetics of epoxy compositions curing in the frameworks of one-step autocatalytic reaction model has been demonstrated. Obtained kinetic parameters were used to predict the curing kinetics under isothermal conditions and for comparative analysis of the compositions

RÜLFS CRAMP AND OTHER PAROXYSMAL DYSKINESIA

Paroxysmal dyskinesia comprise a significant and fascinating part of movement disorders, which represent a diagnostic challenge for neurologists working on the borderlands of psychiatry and epilepsy. The current classification based on the relation of attacks to a movement is supported by the response to treatment and genetic difference. We reviewed clinical characteristics and the main advances in genetics of these unique, usually hereditary diseases. Clinical diagnosis remains the key to the treatment choice. Psychogenic causes are common in sporadic cases, but paroxysmal dyskinesia secondary to systemic or primary neurological disorders should not be missed and warrant careful investigation

Levodopa-carbidopa intestinal gel in the treatment of patients with parkinson disease: Results of a 12-month open study

© 2017, Media Sphera. All rights reserved.Objective: To evaluate the long-term safety and efficacy of intrajejunal levodopa-carbidopa intestinal gel (LCIG) infusion in the treatment of patients with severe stages of Parkinson disease (PD) who did not respond adequately to treatment with oral drugs. Material and methods: A large-scale international prospective open-label 54-week study of LCIG in patients with PD with severe motor fluctuations was carried out. A total of 48 patients were enrolled in Russia, 46 patients (95.8%) had PEG-J inserted, and 43 of them completed the study. The safety, including adverse events (AEs), infusion system and pump failures analysis, number of patients completely terminated the study, and efficacy (duration of “off” periods, “on” periods with or without troublesome dyskinesias, UPDRS scores, Clinical Global Impression, Quality of Life (PDQ-39, EQ-5D и EQ-VAS) dynamics, an analysis of patient’s diaries) were assessed throughout the whole study. Results: The majority of AEs were mild or moderate with most AEs connected with infusion system application (28.3% patients) including procedure pain. Serious AEs were registered in 8 patients (16.7%). 3 patients (6.3%) discontinued their participation in the study due to AEs. Mean duration of “off” periods by the end of the study decreased by 5.35±2.59 hours (p<0.001), duration of “on” periods without troublesome dyskinesia increased by 5.74±3.91 hours (p<0.001), reduction of “on” periods duration with troublesome dyskinesia became statistically significant by week 36 (p=0.020). The statistically significant improvement of UPDRS (generally and in respect to sub-scales), Clinical Global Impression, and Quality of Life scores was observed throughout the study. Levodopa dose remained stable throughout the 54 treatment weeks. Forty-three patients (93.5%) received LCIG monotherapy throughout the whole study. Conclusion: LCIG intrajejunal infusion during 54 weeks showed the favorable safety profile, high tolerability, and efficacy in PD motor symptoms correction

Levodopa-carbidopa intestinal gel in the treatment of patients with parkinson disease: Results of a 12-month open study

© 2017, Media Sphera. All rights reserved.Objective: To evaluate the long-term safety and efficacy of intrajejunal levodopa-carbidopa intestinal gel (LCIG) infusion in the treatment of patients with severe stages of Parkinson disease (PD) who did not respond adequately to treatment with oral drugs. Material and methods: A large-scale international prospective open-label 54-week study of LCIG in patients with PD with severe motor fluctuations was carried out. A total of 48 patients were enrolled in Russia, 46 patients (95.8%) had PEG-J inserted, and 43 of them completed the study. The safety, including adverse events (AEs), infusion system and pump failures analysis, number of patients completely terminated the study, and efficacy (duration of “off” periods, “on” periods with or without troublesome dyskinesias, UPDRS scores, Clinical Global Impression, Quality of Life (PDQ-39, EQ-5D и EQ-VAS) dynamics, an analysis of patient’s diaries) were assessed throughout the whole study. Results: The majority of AEs were mild or moderate with most AEs connected with infusion system application (28.3% patients) including procedure pain. Serious AEs were registered in 8 patients (16.7%). 3 patients (6.3%) discontinued their participation in the study due to AEs. Mean duration of “off” periods by the end of the study decreased by 5.35±2.59 hours (p<0.001), duration of “on” periods without troublesome dyskinesia increased by 5.74±3.91 hours (p<0.001), reduction of “on” periods duration with troublesome dyskinesia became statistically significant by week 36 (p=0.020). The statistically significant improvement of UPDRS (generally and in respect to sub-scales), Clinical Global Impression, and Quality of Life scores was observed throughout the study. Levodopa dose remained stable throughout the 54 treatment weeks. Forty-three patients (93.5%) received LCIG monotherapy throughout the whole study. Conclusion: LCIG intrajejunal infusion during 54 weeks showed the favorable safety profile, high tolerability, and efficacy in PD motor symptoms correction